Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rintodestrant - G1 Therapeutics

Next Previous
Drug Profile

Rintodestrant - G1 Therapeutics

Alternative Names: G1T-48

Latest Information Update: 24 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois
  • Developer G1 Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzene derivatives; Carboxylic acids; Ethers; Fluorobenzenes; Small molecules; Thiophenes
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; HER2 negative breast cancer

Most Recent Events

  • 18 Sep 2024 G1 Therapeutics has been acquired by Pharmacosmos
  • 19 Apr 2023 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium (PO)
  • 19 Apr 2023 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Bulgaria (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top